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Resistance to thyroid hormone (RTH) is a clinical disorder without specific and effective therapeutic
strategy, partly due to the lack of structural mechanisms for the defective ligand binding by mutated
thyroid hormone receptors (THRs). We herein uncovered the prescription drug roxadustat as a novel
THRb-selective ligand with therapeutic potentials in treating RTH, thereby providing a small molecule
tool enabling the first probe into the structural mechanisms of RTH. Despite a wide distribution of the
receptor mutation sites, different THRb mutants induce allosteric conformational modulation on the
same His435 residue, which disrupts a critical hydrogen bond required for the binding of thyroid
hormones. Interestingly, roxadustat retains hydrophobic interactions with THRb via its unique phenyl
extension, enabling the rescue of the activity of the THRb mutants. Our study thus reveals a critical
receptor allosterism mechanism for RTH by mutant THRb, providing a new and viable therapeutic
strategy for the treatment of RTH.
INTRODUCTION
The thyroid hormone receptors (THRs) are nuclear hormone receptors regulated by endogenous thyroid hor-
mones, including the inactive prohormone thyroxine (T4) and the bioactive hormone 3,30,5-triiodothyronine
(T3), which are critical for development regulation and metabolic homeostasis. Encoded by two different
genes, THRa and THRb are two main receptor subtypes with overlapping and differential characteristics
in tissue distribution, ligand binding, and biological functions (Cheng et al., 2010). Notably, small molecules
with THRb subtype-selective binding activity are of great value for clinical purposes for their beneficial effects
on cholesterol (Baxter and Webb, 2009). Resistance to thyroid hormone (RTH) is a clinical disorder with
impaired sensitivity to thyroid hormones at the cellular and tissue level, characterized by elevated thyroid
hormone level and a normal or slightly increased thyroid-stimulating hormone level, leading to variable de-
grees of mental and growth abnormalities (Ortiga-Carvalho et al., 2014; Refetoff et al., 1993). Although the
defects in any of the processes in thyroid hormone transport and synthesis can all contribute to RTH, in most
cases the disorder involves defective thyroid hormone receptors, resulting in reduced T3 binding and disrup-
tive thyroid hormone signaling (Dumitrescu and Refetoff, 2013). Most RTHmutations identified are located in
the ligand-binding domain (LBD) of THRb, leading to resistance to thyroid hormone b (RTHb). Although the
elevated thyroid hormone levels associated with the mutations in THRb or the applications of thyroid hor-
mone analogues can compensate the defective THRb activity, the excess ligands may lead to the over-stim-
ulation of THRa associated with more severe impairment, emphasizing the importance of the development
of THRb-selective ligands in treating RTH (Wagner et al., 2001; Martinez et al., 2009). Despite much encour-
aging progress in developing thyroid hormone analogues for the treatment of RTHb (Hassan and Koh, 2008),
their further development and clinical application have been limited by variations in treatment outcomes,
selective mutation distributions, or tissue toxicity (Groeneweg et al., 2017). Furthermore, the wide distribu-
tions of the THRbmutation sites suggest diversemechanisms for RTHb and their specific therapeutic strategy
accordingly (Huber et al., 2003). As such, the development of novel ligands with preferential affinity to THRb
while targeting individual THRb mutants is of the utmost importance for the treatment of RTHb.
The negative feedback loop of the hormone active form T3 through binding to THRs plays important roles
in the thyroid hormone homeostasis (Chiamolera and Wondisford, 2009). As ligand-regulated nuclear
receptors (Mangelsdorf, 1995), THRs have a structurally conserved LBD that allows the binding of distinct
ligands (Burris et al., 2013). The binding of ligands is regulated by a combination of hydrophobic and hy-
drophilic interactions with the residues in the ligand-binding pocket located in the receptor LBD. Following
the ligand binding, the function of THRs is mediated through the selective recruitment or release of specific
coregulators, like the family of steroid receptor coactivators (SRCs) (Li et al., 2003; Jin and Li, 2010; SavkuriScience 20, 489–496, October 25, 2019 ª 2019 The Author(s).
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Figure 1. THR Subtype-Selective Binding and Activity of Roxadustat
(A) Dose-response curves of the THRa and THRb LBDs to recruit the coactivator SRC1 motif in response to roxadustat
measured by AlphaScreen assays.
(B) The EC50 values of various co-activator peptide motifs to the THRa and THRb LBDs in response to roxadustat by
AlphaScreen assays.
(C and D) Dose-response curves of the transactivation activity of the THRa and THRb LBDs in response to T3 (C) or
roxadustat (D) by cell-based luciferase assays, respectively. Values are the means G SD of three independent values.and Burris, 2004), as a heterodimeric complex with retinoid X receptor (RXR) (Putcha et al., 2012; Kojetin
et al., 2015; Mangelsdorf and Evans, 1995). Moreover, since ligand binding and ligand-mediated cofactors
recruitment are crucial for functions mediated by THRs, the LBD and the ligand-binding pocket have been
the focus of intensive structural study, providing the molecular basis for the thyroid hormone binding and
receptor subtypes selectivity. However, the precise molecular mechanisms underlying the defective thyroid
hormone binding by various mutant receptors remain unclear. The structural insights into the defective
ligand binding by THRb mutants will be imperative for the rational design of effective mutant-specific
ligands for the treatment of RTH.
RESULTS
Identification of Roxadustat as a THRb-Selective Ligand
In search of novel ligands for THRs, we used THRb LBD as bait to screen chemical libraries based on
AlphaScreen biochemical assay, which determines the efficacy of small molecules in recruiting coregulator
peptides to the THRb LBD. Surprisingly, roxadustat (FG-4592), a first-in-class oral hypoxia-inducible factor
prolyl hydroxylase (HIF-PH) inhibitor (Bouchie, 2013) and recently approved drug for the treatment of
anemia, was revealed as a positive THRs activator. With a molecular scaffold distinct from native thyroid
hormones (Figure S1), roxadustat strongly promoted the interaction of both THRa and THRb with various
coactivator LXXLL motifs from the family of steroid receptor coactivators (SRC1, SRC2, and SRC3) with
EC50s of about 25 and 15 nM, respectively (see Transparent Methods and Figures S2, 1A, and 1B), suggest-
ing an agonist nature of the ligand. In agreement with AlphaScreen results, cell-based mammalian one-
hybrid reporter assay was performed to confirm the efficacy of roxadustat in activating THRs in mammalian
cells (Figures 1C and 1D), further affirming that roxadustat is a highly potent THRs ligand with biological490 iScience 20, 489–496, October 25, 2019
Figure 2. Structural Analysis of the Recognition of Roxadustat by THRb LBD
(A) The structure of roxadustat bound with THRb LBD in cartoon representation. THRb LBD is colored in lime, and the
SRC2-3 motif is in salmon. The bound roxadustat is shown in stick representation with carbon, nitrogen, and oxygen
atoms depicted in yellow, blue, and red, respectively.
(B) A 2Fo-Fc electron density map (1.0 d) showing the bound roxadustat.
(C) Schematic representation of the roxadustat-THRb interaction. The arrows and the lines represent the hydrogen bonds
and hydrophobic interactions between ligand and LBD residues, respectively.
(D) Superposition of the T3-bound THRb (light blue) with the roxadustat-bound THRb (lime), where T3 is in cyan and
roxadustat is in yellow.functions. Interestingly, both AlphaScreen and reporter assay indicated that roxadustat interacts with THRb
with higher potency compared with THRa (Figure 1), suggesting a THRb-selective binding nature of
roxadustat.
Structural Basis for the Recognition of Roxadustat by THRb LBD
To determine the molecular basis of the binding selectivity of roxadustat to THRb, we solved the crystal
structures of THRb LBD complexed with roxadustat (Table S1). The structure reveals that the roxadustat-
bound THRb adopts a canonical active conformation in a three-layer helical sandwich arrangement that
resembles most agonist-bound nuclear receptor structures (Figure 2A), in agreement with the agonist ac-
tivity of roxadustat on THRs by both AlphaScreen and reporter assays (Figures S2 and 1). The existence of
roxadustat was apparent from the highly revealing electron density map shown in Figure 2B, whose inter-
action with THRb was stabilized by a combination of hydrogen bonds and hydrophobic interactions (Fig-
ure 2C). Superposition of the roxadustat-bound THRb structure with the T3-bound THRb (PDB ID 3GWS)
(Nascimento et al., 2006) showed that roxadustat aligned well with the native ligand T3 and occupied
the similar binding site in the THRb pocket (Figure 2D). Notably, structural alignment of THRb-bound rox-
adustat with various THR ligands available at PDB revealed that roxadustat shares a conserved carboxyl
head group for all the THR ligands (Figure S3) (Nascimento et al., 2006; Sandler et al., 2004; HuberiScience 20, 489–496, October 25, 2019 491
Figure 3. Structural Basis for the THRb Selectivity by Roxadustat
A structural alignment of the structures of T3/THRa LBD (gray) and roxadustat/THRb LBD (lime) is shown in cartoon
representations with T3 and roxadustat shown in cyan and yellow, respectively. Differential conformations of the
backbone (A) and individual residue side chains (B) between THR a and THRb LBD that contribute to the receptor
selectivity are indicated by red arrows.et al., 2003; Dow et al., 2003; Ye et al., 2003; Borngraeber et al., 2003; Hangeland et al., 2004; Bleicher et al.,
2008; Koehler et al., 2006). Surprisingly, instead of a conserved hydrophilic hydroxyl group at the tail shared
by all the other THR ligands, roxadustat has a hydrophobic phenyl extension at the corresponding site,
which results in mainly hydrophobic interactions with THRb at this position (Figure 2C), suggesting a unique
functional nature of roxadustat as a THR ligand.
Structural Basis for the THRb Selectivity by Roxadustat
A structural alignment of the roxadustat-bound THRb structure with the T3-bound THRa (PDB ID 2H77)
(Nascimento et al., 2006) revealed a structural mechanism for the THRb receptor selectivity by roxadustat
(Figure 3). Despite that roxadustat overall aligns well with T3, a unique structural feature of roxadustat
different from T3 is its extended hydrophobic phenyl group, suggesting that a larger hydrophobic cavity
is needed for the effective ligand binding. Interestingly, the helix 10 of THRb shifts outward to make extra
space for the phenyl extension of roxadustat in comparison with that of THRa (Figure 3A). Similarly, the side
chains of the hydrophobic residues, such as F272 and F269 of THRb, display differential conformations
compared with their corresponding residues of THRa, resulting in a larger pocket size to accommodate
the binding of roxadustat (Figure 3B). In summary, differential conformations between THRb and THRa
on the backbone and individual residue side chains coupled with the unique larger phenyl extension of
roxadustat contribute to the THR subtype selectivity of roxadustat, highlighting the differential roles of
THR pocket residues in recognizing various ligands.
Roxadustat Overcomes Thyroid Hormone Resistance Caused by Receptor Mutations
Given the unique nature and scaffold of roxadustat as a THRb-selective ligand, we next investigated its abil-
ity in activating THRb associated with thyroid hormone resistance. As shown in Figure 4, treatment with rox-
adustat significantly induced the transcriptional activity of wild-type THRb in Gal-4 driven reporter assays,
to a lesser extent than that of T3. As expected, the native ligand T3 abolished or substantially diminished
the transcriptional activity of four THRb mutants associated with thyroid hormone resistance, V264D,
H435L, R438H, and R438W, respectively (Wakasaki et al., 2016; Nomura et al., 1996; Sabet and Pallotta,
2011; Narumi et al., 2010). Surprisingly, the treatment of roxadustat either enhanced or retained the tran-
scriptional activity of these THRb mutants, all leading to higher induced transcriptional activity than those
of T3 (Figure 4). The thermal stability analysis showed that both T3 and roxadustat increased the thermal
stability of TRb wild-type, with a higher Tm value for the T3 treatment (Figure S4). In contrast, the binding
of roxadustat resulted in higher Tm values for four TRbmutants than that of T3 (Figure S4). All these results
suggest a potential advantage of roxadustat over native thyroid hormones in treating thyroid hormone
resistance caused by specific mutations.
Structural Mechanism for the Roxadustat in Rescuing Thyroid Hormone Resistance
Although all four mutant residues are located in the THRb LBD, H435 is the only one that directly contacts
ligands T3 or roxadustat, whereas the rest of the mutant residues are located outside the ligand-binding
pocket, not in the range to form intimate contacts with the ligands (Figure S5), which makes us wonder492 iScience 20, 489–496, October 25, 2019
Figure 4. Roxadustat Overcomes Thyroid Hormone Resistance Caused by Thyroid Hormone Receptor Mutations
The fold induction of transcriptional luciferase activity by THR ligands in reporter assays. 293T cells were co-transfected
with pG5Luc reporter together with the plasmids encoding various THRb mutant LBDs fused with the Gal4 DNA-binding
domain. After transfection, cells were treated with DMSO or 2 mM T3 or 2 mM roxadustat. The dashed line indicates one-
fold activation by the ligands compared with the DMSO treatment. Values are the means G SD of three independent
values.how these mutants influence the ligand binding. To unravel the molecular basis for the RTH of the THRb
mutants and further their beneficial susceptibility to roxadustat, we performed structural studies on the
THRb mutants complexed with roxadustat. The data statistics and the refined structures are summarized
in Table S1. For all four THRb mutants whose crystal structures have been solved as shown in Figure S6,
roxadustat was clearly observed to fit in the electron density maps in the ligand-binding pockets. The struc-
tural analysis further revealed an apparent conformational change of residue H435 on helix 10 of THRb for
all four mutants, resulting in the loss of a critical hydrogen bond between THRb and a critical hydroxy group
of T3 (Figure 5), which is also conserved for the other THR ligands identified so far (Figure S3), explaining
the severely reduced THRb activity by T3 (Figure 4). Specifically, in addition to the direct mutation of H435
to the hydrophobic leucine of THRbH435L (Figure 5A), the allosteric conformational changes of THRbH435
were coupled with several intermediate structural changes, predominantly in helix 10, which were initiated
by mutants R438H, R438W, or V264D, consequently leading to impaired T3 binding (Figures 5B–5D).
Notably, both R438H and R438W are located on the helix 10, thereby directly affecting its conformation
(Figures 5B and 5C). Although the mutant V264D is located far away at the end of helix 3, the residue
Asp that resulted from the mutation provides a hydrogen bond donor to create a new hydrogen bond
with H441 on the helix 10, which serves as transducer to relay conformation changing information to the
helix 10 and H435 (Figure 5D).
In contrast to the reduced binding of T3 by THRbmutants due to the loss of a critical hydrogen bond donor/
acceptor contributed by H435, roxadustat retains the effective binding activity (Figure 4) owing to the
hydrophobic interactions with THRbmutants via its unique phenyl extension at the corresponding position,
which was unaffected by the conformational changes of the polar H435 residue (Figure 5). The structures
therefore have uncovered the mechanisms for the roxadustat in rescuing the activity of the THRb mutants,
highlighting the critical roles of the unique nature of the hydrophobic interaction between roxadustat and
THRbmutants (Figure 5). Collectively, the THRbmutants we studied dictate the discrimination between T3
and roxadustat via the modulation of the conformation of a critical residue H435 either directly or alloste-
rically, resulting in differential effects of the mutant receptors to native thyroid hormones and roxadustat.
DISCUSSION
Despite the physiological and pharmaceutical importance of RTHb, there is still specific therapeutic strat-
egy available, partly owing to the limited understanding of the structural mechanisms for the defective
ligand binding by THRb mutants. Indeed, the lack of ligands that efficiently bind THR mutants makes the
structural study of RTH difficult, given the critical roles of the ligand binding in the stabilization of THRs
for biochemical and structural studies, which is evidenced by the unavailability of any apo-THR crystal struc-
tures. Here, we report the identification of an anemia drug roxadustat as a novel modulator for THRs with a
therapeutic potential in the treatment of RTH, thereby providing a small molecule tool enabling the firstiScience 20, 489–496, October 25, 2019 493
Figure 5. Structural Mechanism for the Roxadustat to Activate the THRb Mutants Associated with Thyroid
Hormone Resistance
(A–D) Overlays of T3-bound THRb WT (light blue) with the roxadustat-bound THRb mutants (lime) shown as cartoon
representations, with T3 and roxadustat shown in cyan and yellow, respectively. The conformational changes of the
residues involved in the thyroid hormone resistance by THRbmutations are indicated by red arrows. The mutant residues
are shown in salmon red.probe into the structural mechanisms of RTH. In addition to a safe template, our structural and functional
study reveals key structural features that define specific recognition of ligands by mutant THRb and
provides structural mechanisms for designing selective and potent ligands of THRb for the treatment of
RTH.
The physiological function of roxadustat has been linked to HIF-PH signaling pathways. Since roxadustat
also interacts with THRs, the structural mechanism may provide a basis for designing roxadustat-based
compounds that can be used more specifically either for THR- or HIF-PH-regulated diseases, or for a
combinatorial therapy. The beneficial and side effects arising from the cross-interaction with each target
can be optimized by designing new roxadustat-based compounds with more selectivity. Further elucida-
tion of these two disparate signaling pathways of THR and HIF should reveal specific molecular basis for
pharmacological potentials of roxadustat.
Notably, the allosteric regulation has been crucial in regulating receptor function and signal transduction,
from inter-molecular domain interactions to intramolecular interactions among DNA (Christopoulos et al.,
2014; Putcha and Fernandez, 2009), although the detailed structural mechanisms still need to be further
elucidated. Given the highly conserved nature of the ligand-binding pockets, the understanding of the
allosterism will reveal more insights into the mechanisms for fine-tuning nuclear receptor function by small
molecules, which may lead to a new drug-design strategy targeting allosteric and function-selective sites in
modulating nuclear receptor activity (Fernandez, 2018).
Limitations of the Study
Here we identified a small molecule tool enabling the first probe into the structural mechanisms of RTH and
further revealed a molecular mechanism for the defective ligand binding of RTH, thus providing a structural
template for designing small molecules in treating RTH. Since the study is based on biochemical and
crystallographic assays, the pharmacological potentials of the ligands on in vivo animal models will be
the subject of future studies.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.494 iScience 20, 489–496, October 25, 2019
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Figure. S1. Chemical structures of roxadustat and T3, related to Figure 1. 
Roxadustat (FG-4592) is a potent hypoxia-inducible factor (HIF) prolyl 
hydroxylase inhibitor (PHI) for the treatment of anemia, Triiodothyronine (T3) is a 
physiological ligand for THRs.
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Figure. S2. Roxadustat promotes the interaction of co-activator LXXLL 
motifs with THRs, related to Figure 1. Modulation of the interaction of THR 
LBDs with various co-activator LXXLL motifs motifs in response to 1 µM 
roxadustat was shown by AlphaScreen assays. The peptide sequences are listed in 
experimental procedures. Values are the means±SD of three independent.
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Figure. S3. Superposition of THRβ-bound roxadustat with various THRβ-bound 
ligands available at PDB, related to Figure 2. Roxadustat (yellow) shares the conserved 
carboxyl head but not the hydroxy tail groups (both are indicated by red arrows) of THR 
ligands. The unique hydrophobic benzyl extension of roxadustat is indicated by a blue 
arrow.
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Figure S4. Roxadustat significantly improved the thermostability of TRβ, related 
to Figure 4. (A) Thermal shift assay fluorescence signals obtained for wildtype 
TRβ/SRC2-3 with and without ligands. Tm values of TRβ/SRC2-3 were shifted 8℃
and 6℃ by T3 and roxadustat, respectively, compared to DMSO. (B) Thermostability
characterization of the interactions between TRβ mutants and ligands . Data represent 
the mean ± SD (n=3). Representative results from three independent experiments are 
shown. 
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Figure S5. The locations of the 4 THRβ mutations associated with thyroid hormone 
resistance, related to Figure 4. An overlay of the T3-bound THRβ (light blue) with the 
roxadustat-bound THRβ (lime) shown in ribbon (A) and cartoon (B) representations, 
respectively, with T3 and roxadustat shown in cyan and yellow, respectively. The 
wildtype residues are shown in sticks. 
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Figure S6. Structural validation of the binding of roxadustat to four THRβ mutants, 
related to Figure 5. The structure of roxadustat bound with THRβ mutants in cartoon 
representation. THRβ LBD is colored in lime. The bound roxadustat is shown in stick 
representation with carbon, nitrogen and oxygen atoms depicted in yellow, blue and red, 
respectively. 2Fo-Fc electron density map (1.0 σ ) showing the bound roxadustat. The 
mutant residues are shown in salmon red. 
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Transparent Methods 
Protein preparation  
Mutant human THRβ LBDs were prepared using the QuikChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA, USA) with wild-type THRβ LBD (residues 202-461) as the template. The 
human THRα LBD (residues 148-410), human THRβ LBD and mutant THRβ LBDs were expressed as 
an amino-terminal 6*His fusion protein from the expression vector pET24a (Novagen, Madison, WI, 
USA), respectively. BL21 (DE3) cells transformed with expression plasmids were grown in lysogeny 
broth at 30 ºC to an OD600 of 0.8 and induced with 0.5mM isopropyl isopropyl β-D-thiogalactoside 
(IPTG) at 22 ºC for 6 h. Cells were collected and sonicated in extraction buffer (20mM Tris pH 8.0, 
150mM NaCl, 10% glycerol and 25mM imidazole) on ice. The lysate was centrifuged at 20,000 r.p.m. 
for 30 min and the supernatant was loaded on a 5-ml NiSO4-loaded HiTrap HP column (GE 
Healthcare, Piscataway, NJ, USA). The column was washed with extraction buffer and the protein was 
eluted with a gradient of 25–500mM imidazole. The THR LBDs were further purified with a Q-
Sepharose column (GE Healthcare, Piscataway, NJ, USA), followed by gel filtration using a HiLoad 
26/600 Superdex 200 column (GE Healthcare, Piscataway, NJ, USA). To prepare the wild type and 
mutant THRβ LBD protein-ligand complexes, we added a fivefold molar excess of roxadustat 
(TargetMol, China) and a two-fold molar of a SRC2-3 peptide (ENALLRYLLDKD) to the purified protein, 
followed by filter concentration to 10 mg mL-1.  
 
Coregulator Binding Assays 
The binding of the various coregulator peptide motifs to THR LBDs in response to ligands was 
determined by AlphaScreen assays using a hexahistidine detection kit from Perkins-Elmer as 
described before (1). The experiments were conducted with approximately 20-40 nM receptor LBDs 
and 20 nM biotinylated coregulator peptides in the presence of 5 µg mL-1 donor and acceptor beads in 
a buffer containing 50 mM MOPS, 50 mM NaF, 0.05 mM CHAPS, and 0.1 mg mL-1 bovine serum 
albumin, all adjusted to a pH of 7.4. The peptides with an N-terminal biotinylation are listed below. 
SRC1-2, SPSSHSSLTERHKILHRLLQEGSP; 
SRC2-3, QEPVSPKKKENALLRYLLDKDDTKD; 
SRC3-3, PDAASKHKQLSELLRGGSG. 
 
Crystallization and structure determination 
The crystals of THRβ LBD/roxadustat/SRC2-3 complex were grown at room temperature in hanging 
drops containing 1.0 μL of the above protein-peptide solutions and 1.0 μL of well buffer containing 0.2 
M sodium citrate and 20% polyethylene glycol 3350. The crystals of THRβ(V264D)/roxadustat/SRC2-3 
complex were grown in well buffer contained 0.1 M Sodium acetate trihydrate pH 4.6 and 2.0 M 
Sodium formate. The crystals of THRβ(H435L)/roxadustat/SRC2-3 complex were grown in well buffer 
contained 0.2 M Sodium tartrate dibasic dihydrate and 20% w/v Polyethylene glycol 3,350. The crystals 
of THRβ(R438H)/roxadustat/SRC2-3 complex were grown in well buffer contained 100mM NaCl and 
20% PEG 4000. The crystals of THRβ(R438W)/roxadustat/SRC2-3 complex were grown in well buffer 
contained 0.1 M Sodium cacodylate trihydrate pH 6.5 and 1.4 M Sodium acetate trihydrate. These 
crystals appeared within 1 day and grew to their full size within 2-3 days at room temperature. All 
crystals were directly flash-frozen in liquid nitrogen for data collection. The observed reflections were 
reduced, merged and scaled with DENZO and SCALEPACK in the HKL2000 package (2). The 
	
structures were determined by molecular replacement in the CCP4 suite. Manual model building was 
carried out with Coot (3), followed by Refmac5 refinement in the CCP4 suite. 
 
Transient transfection assay 
HEK-293T cells (ATCC) were maintained in Dulbecco’s Modified Eagle Medium (DMEM) containing 
10% fetal bovine serum and were transiently transfected using Lipofectamine 2000 (Invitrogen). All 
mutant THR plasmids were created using the Quick-Change Site-Directed Mutagenesis Kit 
(Stratagene). Before 24 h of transfection, cells were plated in 24-well plates at a density of 5×104 cells 
per well. The cells were transfected with 200 ng Gal4-LBDs of various THRs, respectively, together 
with 200 ng of pG5Luc reporter (Promega). Ligands were added 5 h after transfection. Cells were 
harvested 24 h later for luciferase assays with a dual-luciferase reporter assay system (Promega). The 
luciferase activities were normalized to Renilla activity as an internal control.  
 
Thermal stability analysis.  
Thermostability analysis used ABI 7500 Fast, an RT-PCR instrument, as described before (4-5). Briefly, 
purified protein were preincubated 2 hours with two-fold molar coregulator peptides and DMSO or five-
fold molar excess T3 or FG-4592, respectively.  Standard assay conditions (20 μL) contain 12.5 μL 
protein complex (24uM), 7.5ul Protein Thermal Shift Tm buffer and 1/1000 volume of ROX dye (Protein 
Thermal ShiftTM Dye Kit, Applied Biosystems, USA). Thermal shift assays were performed in 96-well 
PCR plates which were heated from 40°C to 80°C at a rate of 1°C/min and the fluorescence data were 
obtained on 7500 fast real-time PCR instrument. The 50% of maximum temperature (Tm) value of 
protein/ cofactor/ compound was analyzed by GraphPad Prism 7 and fitted using Boltzmann sigmoid 
curves. All experiments were performed in triplicates.  
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